154 related articles for article (PubMed ID: 33109533)
1. EBV Positivity and Programmed Death-ligand 1 Expression in Diffuse Large B-cell Lymphoma: A Systematic Review.
Barzyk GA; Sheriff V
Anticancer Res; 2020 Nov; 40(11):5951-5968. PubMed ID: 33109533
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
[TBL] [Abstract][Full Text] [Related]
4. Programmed cell death-ligand 1 (PD-L1)
Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Mihashi Y; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M
Clin Exp Med; 2022 Aug; 22(3):411-419. PubMed ID: 34515880
[TBL] [Abstract][Full Text] [Related]
5. EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression.
Xue T; Wang WG; Zhou XY; Li XQ
Pathology; 2018 Dec; 50(7):725-729. PubMed ID: 30389217
[TBL] [Abstract][Full Text] [Related]
6. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
[TBL] [Abstract][Full Text] [Related]
7. Expression of co-inhibitory molecules B7-H4 and B7-H1 in Epstein-Barr virus positive diffuse large B-cell lymphoma and their roles in tumor invasion.
Jiang Y; Lin J; Zhang J; Lu S; Wang C; Tong Y
Pathol Res Pract; 2019 Dec; 215(12):152684. PubMed ID: 31679792
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological analysis of neoplastic PD-L1-positive EBV
Takahara T; Satou A; Ishikawa E; Kohno K; Kato S; Suzuki Y; Takahashi E; Ohashi A; Asano N; Tsuzuki T; Nakamura S
Virchows Arch; 2021 Mar; 478(3):541-552. PubMed ID: 32803453
[TBL] [Abstract][Full Text] [Related]
9. EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.
Cristino AS; Nourse J; West RA; Sabdia MB; Law SC; Gunawardana J; Vari F; Mujaj S; Thillaiyampalam G; Snell C; Gough M; Keane C; Gandhi MK
Blood; 2019 Dec; 134(25):2261-2270. PubMed ID: 31856276
[TBL] [Abstract][Full Text] [Related]
10. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
Anastasiadou E; Stroopinsky D; Alimperti S; Jiao AL; Pyzer AR; Cippitelli C; Pepe G; Severa M; Rosenblatt J; Etna MP; Rieger S; Kempkes B; Coccia EM; Sui SJH; Chen CS; Uccini S; Avigan D; Faggioni A; Trivedi P; Slack FJ
Leukemia; 2019 Jan; 33(1):132-147. PubMed ID: 29946193
[TBL] [Abstract][Full Text] [Related]
14. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S
Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma.
Kwon HJ; Yang JM; Lee JO; Lee JS; Paik JH
J Transl Med; 2018 Nov; 16(1):320. PubMed ID: 30458835
[TBL] [Abstract][Full Text] [Related]
16. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
Kiyasu J; Miyoshi H; Hirata A; Arakawa F; Ichikawa A; Niino D; Sugita Y; Yufu Y; Choi I; Abe Y; Uike N; Nagafuji K; Okamura T; Akashi K; Takayanagi R; Shiratsuchi M; Ohshima K
Blood; 2015 Nov; 126(19):2193-201. PubMed ID: 26239088
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
18. Frequent expression of PD-L1 in BLS-type diffuse large B-cell lymphoma: implications for aggressiveness and immunotherapy.
Yang CF; Yu YT; Wang SH; Chen YP; Chen TY; Hsu CY; Medeiros LJ; Chang KC
Pathology; 2024 Apr; 56(3):367-373. PubMed ID: 38290893
[TBL] [Abstract][Full Text] [Related]
19. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.
Liu Y; Ma J; Yu K; Li M; Liu F; Yan Q; Wang Z; Guo S
Pathol Res Pract; 2018 Apr; 214(4):507-512. PubMed ID: 29598887
[TBL] [Abstract][Full Text] [Related]
20. PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro.
Quan L; Chen X; Liu A; Zhang Y; Guo X; Yan S; Liu Y
PLoS One; 2015; 10(9):e0136476. PubMed ID: 26361042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]